Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York. Fouad Namouni, senior vice president, Head of Oncology, will answer questions about the company at 3:00 p.m. EDT.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005741/en/

Bristol-Myers Squibb Company
Media:
Ken Dominski, 609-252-5251
[email protected]
or
Investors:
Tim Power, 609-252-7509
[email protected]
or
Bill Szablewski, 609-252-5894
[email protected]

Source: Bristol-Myers Squibb Company

You May Also Be Interested In

• Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
• Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes
• Gargle Expands Dental Marketing Insights to Help Practices Measure Visibility Across Google and AI Search